89868-13-3

Basic information

• Product Name: 3-Chloro-6-phenyl-pyridazin-4-ol
• Synonyms: 3-Chloro-6-phenyl-pyridazin-4-ol
• CAS NO: 89868-13-3
• Molecular Formula: C₁₀H₇ClN₂O
• Molecular Weight: 206.63
• EINECS: -0
• Mol File: 89868-13-3.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 433.464°C at 760 mmHg
• Flash Point: 215.952°C
• Appearance: /
• Density: 1.363
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.628
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 3-Chloro-6-phenyl-pyridazin-4-ol(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Chloro-6-phenyl-pyridazin-4-ol(89868-13-3)
• EPA Substance Registry System: 3-Chloro-6-phenyl-pyridazin-4-ol(89868-13-3)

Safety Data

• Hazardous Substances Data: 89868-13-3(Hazardous Substances Data)

Usage

General Description

3-Chloro-6-phenyl-pyridazin-4-ol is a chemical compound with the formula C11H8ClN3O, falling under the category of pyridazines. Pyridazines are heterocyclic compounds consisting of a six-membered ring with two nitrogen atoms opposite to each other and include other biologically active compounds. As a specific compound, 3-Chloro-6-phenyl-pyridazin-4-ol does not have extensive research or data available regarding its usage or properties. However, as with similar compounds, it is presumed to have potential applications in pharmaceuticals or other chemical reactions. Due to the lack of extensive research, its risk and safety profile is also not fully known.

InChI:InChI=1/C10H7ClN2O/c11-10-9(14)6-8(12-13-10)7-4-2-1-3-5-7/h1-6H,(H,12,14)

Upstream product

• 64942-62-7 3,4-dichloro-6-phenylpyridazine 
• 87769-64-0 4,5,-dihydro-6-phenyl-2-(phenylmethyl)-3(2H)-pyridazinone 
• 2051-95-8 succinylbenzene 
• 1011-46-7 6-phenyl-2,3,4,5-tetrahydropyridazin-3-one 

Downstream Products

• 89868-16-6 6-phenyl-4-pyridazol 
• 89868-15-5 3-(dimethylamino)-6-phenyl-4-pyridazinol 
• 886208-67-9 6-phenyl-3-(4-(pyrimidin-2-yl)piperazin-1-yl)pyridazin-4-ol 
• 886208-70-4 4-chloro-6-phenyl-3-(4-pyrimidin-2-yIpiperazin-1-yl)pyridazine 
• 1449104-98-6 4-(4-methoxyphenoxy)-6-phenylpyridazin-3-amine 
• 1449104-99-7 1-(4-bromophenyl)-3-[4-(4-methoxyphenoxy)-6-phenylpyridazin-3-yl]urea 
• 1449105-00-3 4-bromo-N-[4-(4-methoxyphenoxy)-6-phenylpyridazin-3-yl]benzamide 
• 1449105-01-4 ethyl 2-[4-(4-methoxyphenoxy)-6-phenylpyridazin-3-ylamino]acetate 
• 1449105-02-5 2-[4-(4-methoxyphenoxy)-6-phenylpyridazin-3-ylamino]acetic acid 
• 1449105-03-6 N-(4-bromophenyl)-2-[4-(4-methoxyphenoxy)-6-phenylpyridazin-3-ylamino]acetamide 
• 1449104-97-5 3-chloro-4-(4-methoxyphenoxy)-6-phenylpyridazine 

Relevant articles and documents

FORMULATIONS CONTAINING PYRIDAZINE COMPOUNDS

The invention relates to chemical compounds, compositions and methods of making and using the same. In particular, the invention provides selected pyridazine compounds of the formula I are independently hydrogen, hydroxyl, alkyl, alkenyl, alkynyl, alkylene, alkenylene, alkoxy, alkenyloxy, cycloalkyl, cycloalkenyl, cycloalkynyl, cycloalkoxy, aryl, aryloxy, arylalkoxy, aroyl, heteroaryl, heterocyclic, acyl, acyloxy, amino, imino, azido, thiol, thioalkyl, thioalkoxy, thioaryl, nitro, cyano, halo, sulfate, sulfenyl, sulfinyl, sulfonyl, sulfonate, sulfoxide, silyl, silyloxy, silylalkyl, silylthio, ═O, ═S, phosphonate, ureido, carboxyl, carbonyl, carbamoyl, or carboxamide; and X is optionally substituted pyrimidinyl or pyridazinyl, an isomer, a pharmaceutically acceptable salt, or derivative thereof. The invention additional relates to compositions comprising the compounds, and methods of using the compounds and compositions for modulation of cellular pathways, for treatment or prevention of inflammatory diseases, for research, drug screening, and therapeutic applications.

Development of a novel therapeutic suppressor of brain proinflammatory cytokine up-regulation that attenuates synaptic dysfunction and behavioral deficits

We report the development of a novel, aqueous-soluble, safe, small molecule, experimental therapeutic that suppresses injury-induced, proinflammatory cytokine increases in the brain, with resultant attenuation of synaptic protein biomarker loss and improvement in hippocampus-dependent behavioral deficits. A GMP production scheme for the active pharmaceutical ingredient, compound 17, is presented. The development and large-scale availability of this novel compound allow exploration of new, potentially disease-modifying, therapeutic approaches to CNS disorders.

Synthesis of 4-amino-6-phenyl-3(2H)-pyridazinones: A general procedure

-